secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001193125-23-228074
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd appoints William Duke as CFO effective September 1, 2023
----------------------------------------------------------------

- William Duke (51) appointed CFO; previously CFO at Apexigen and Kaleido Biosciences.
- Salary $475,000, initial target bonus 40% of salary, $20,000 signing bonus.
- Received option to purchase 750,000 shares vesting over 4 years.
- Duke led Apexigen through its sale to Pyxis Oncology and completed multiple financings.
- CEO Hering cited Duke's experience as valuable for upcoming VYD222 clinical study and potential EUA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523228074/0001193125-23-228074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523228074/d539466d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-228074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer